NASDAQ:SCNI Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis $2.20 -0.07 (-3.08%) Closing price 07/3/2025 03:03 PM EasternExtended Trading$2.24 +0.04 (+1.82%) As of 07/3/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Scinai Immunotherapeutics Stock (NASDAQ:SCNI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SCNI alerts:Sign Up Key Stats Today's Range$2.17▼$2.3650-Day Range$2.20▼$3.2552-Week Range$1.90▼$8.92Volume73,299 shsAverage Volume235,370 shsMarket Capitalization$2.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel. Read More Receive SCNI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scinai Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SCNI Stock News HeadlinesScinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025June 12, 2025 | prnewswire.comScinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.June 5, 2025 | prnewswire.comPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it. | Crypto Swap Profits (Ad)Scinai Immunotherapeutics Ltd.: Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash BurnMay 30, 2025 | finanznachrichten.deScinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash BurnMay 30, 2025 | prnewswire.comScinai Announces Annual Financial Results for 2024May 7, 2025 | prnewswire.comScinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin DiseasesMay 1, 2025 | prnewswire.comScinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological ConditionsMarch 27, 2025 | prnewswire.comSee More Headlines SCNI Stock Analysis - Frequently Asked Questions How have SCNI shares performed this year? Scinai Immunotherapeutics' stock was trading at $3.35 at the beginning of 2025. Since then, SCNI shares have decreased by 34.3% and is now trading at $2.20. How were Scinai Immunotherapeutics' earnings last quarter? Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) posted its quarterly earnings data on Wednesday, May, 7th. The company reported ($10.40) earnings per share for the quarter. The business had revenue of $0.21 million for the quarter. When did Scinai Immunotherapeutics' stock split? Scinai Immunotherapeutics's stock reverse split before market open on Tuesday, May 21st 2024.The 1-10 reverse split was announced on Tuesday, May 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Scinai Immunotherapeutics? Shares of SCNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Scinai Immunotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scinai Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), AppLovin (APP), e.l.f. Beauty (ELF) and Disc Medicine (IRON). Company Calendar Last Earnings5/07/2025Today7/05/2025Next Earnings (Estimated)8/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCNI Previous SymbolNASDAQ:SCNI CIK1611747 Webwww.scinai.com Phone972-8-930-2529Fax972-8930-2531Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($9.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$4.80 million Net MarginsN/A Pretax Margin728.88% Return on EquityN/A Return on Assets-40.60% Debt Debt-to-Equity Ratio0.06 Current Ratio1.32 Quick Ratio1.32 Sales & Book Value Annual Sales$660 thousand Price / Sales3.33 Cash FlowN/A Price / Cash FlowN/A Book Value$5.10 per share Price / Book0.43Miscellaneous Outstanding Shares1,000,000Free Float391,000Market Cap$2.20 million OptionableNot Optionable Beta2.04 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:SCNI) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.